share_log

Avenue Therapeutics | DEF 14C: Definitive information statements

Avenue Therapeutics | DEF 14C: Definitive information statements

Avenue Therapeutics | DEF 14C：股东委托书决议
美股sec公告 ·  03/18 17:01
Moomoo AI 已提取核心信息
Avenue Therapeutics, Inc. has announced the approval of a reverse stock split by stockholders holding approximately 56% of the voting power. The reverse stock split will be within a range of 30-for-1 to 75-for-1, with the exact ratio to be determined by the board of directors. The board unanimously approved the proposal and recommended stockholder approval. The reverse stock split is intended to be filed with the Secretary of State for the State of Delaware and will take effect no earlier than April 8, 2024. This action has been taken without the need for a stockholder meeting, utilizing written consent in lieu of a meeting, and does not create appraisal or dissenters' rights under Delaware law. The Information Statement regarding this action was...Show More
Avenue Therapeutics, Inc. has announced the approval of a reverse stock split by stockholders holding approximately 56% of the voting power. The reverse stock split will be within a range of 30-for-1 to 75-for-1, with the exact ratio to be determined by the board of directors. The board unanimously approved the proposal and recommended stockholder approval. The reverse stock split is intended to be filed with the Secretary of State for the State of Delaware and will take effect no earlier than April 8, 2024. This action has been taken without the need for a stockholder meeting, utilizing written consent in lieu of a meeting, and does not create appraisal or dissenters' rights under Delaware law. The Information Statement regarding this action was first mailed to stockholders on or about March 18, 2024. The reverse stock split aims to reduce the number of outstanding shares, potentially affecting the market price and liquidity of the common stock. The company's board may choose not to proceed with the reverse stock split if it is not deemed in the best interests of the stockholders.
Avenue Therapeutics, Inc.宣布批准持有约56％投票权的股东进行反向股票分割。反向股票拆分将在30比1至75比1的范围内，确切的比率将由董事会决定。董事会一致批准了该提案，并建议股东批准。反向股票拆分计划向特拉华州国务卿提交，并将不早于2024年4月8日生效。该行动是在不需要举行股东大会的情况下采取的，使用书面同意代替会议，根据特拉华州法律，不会产生评估或持不同政见者的权利。有关此行动的信息声明于2024年3月18日左右首次邮寄给股东。反向股票拆分旨在减少已发行股票的数量，这可能会影响普通股的市场价格和流动性。如果认为反向股票拆分不符合股东的最大利益，则公司董事会可以选择不进行反向股票拆分。
Avenue Therapeutics, Inc.宣布批准持有约56％投票权的股东进行反向股票分割。反向股票拆分将在30比1至75比1的范围内，确切的比率将由董事会决定。董事会一致批准了该提案，并建议股东批准。反向股票拆分计划向特拉华州国务卿提交，并将不早于2024年4月8日生效。该行动是在不需要举行股东大会的情况下采取的，使用书面同意代替会议，根据特拉华州法律，不会产生评估或持不同政见者的权利。有关此行动的信息声明于2024年3月18日左右首次邮寄给股东。反向股票拆分旨在减少已发行股票的数量，这可能会影响普通股的市场价格和流动性。如果认为反向股票拆分不符合股东的最大利益，则公司董事会可以选择不进行反向股票拆分。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息